NFB-05. A family-centered neurocutaneous syndrome clinic in the age of targeted therapies

On April 10, 2020, the FDA approved selumetinib for the treatment of pediatric patients 2 years of age and older with neurofibromatosis type 1 who have symptomatic, inoperable plexiform neurofibromas. This, combined with the 2016 EXIST-3 data showing the efficacy of adjunctive everolimus in the trea...

Descripción completa

Detalles Bibliográficos
Autores principales: Marks, Asher, Antaya, Richard, Balsamo, Lyn, Cardinale, Kathleen, Cheron, Rebecca, Frumberg, David, Gentile, Victoria, Habib, Larissa, Puthenpura, Vidya, Zhang, Hui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Neurofibromatosis and other Predisposition Syndromes
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9165028/
http://dx.doi.org/10.1093/neuonc/noac079.469

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9165028/
http://dx.doi.org/10.1093/neuonc/noac079.469

Ejemplares similares